Role of Epiregulin on Lipopolysaccharide-Induced Hepatocarcinogenesis as a Mediator via EGFR Signaling in the Cancer...

Area of Science:

• Oncology
• Molecular Biology
• Immunology

Background:

• Lipopolysaccharides (LPS) are implicated in hepatocellular carcinoma (HCC) progression.
• The precise molecular mechanisms linking LPS to HCC remain unclear.
• Epiregulin (EREG), an epidermal growth factor (EGF) family member, is hypothesized to mediate LPS-induced HCC.

Purpose of the Study:

• To investigate the role of epiregulin (EREG) in LPS-induced hepatocellular carcinoma (HCC) progression.
• To elucidate the molecular mechanisms by which LPS influences HCC growth and the tumor microenvironment.
• To examine the involvement of EREG and interleukin-8 (IL-8) signaling in LPS-mediated HCC.

Main Methods:

• A mouse xenograft model using Huh7 HCC cells and LX-2 hepatic stellate cells was established.
• Mice received intraperitoneal injections of lipopolysaccharides (LPS) or a control.
• Tumor growth, EREG expression, vascularization (CD34 staining), and angiogenic marker gene expression (RT-PCR, including IL-8) were analyzed.

Main Results:

• LPS administration significantly increased xenograft tumor size and EREG expression in tumor tissues.
• LPS treatment led to increased tumor vascularization and elevated interleukin-8 (IL-8) expression.
• EREG was identified as a key mediator in the LPS-influenced tumor microenvironment.

Conclusions:

• Epiregulin (EREG) plays a critical role in LPS-induced hepatocellular carcinoma (HCC) progression.
• EREG promotes tumor cell growth, migration, and invasion in EGFR-positive HCC cells.
• LPS-induced EREG signaling contributes to tumor neovascularization via IL-8, highlighting a novel therapeutic target.